Fulgent CSO sells 1,688 shares for tax withholding

Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share.

Rhea-AI Filing Summary

Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.

Insider Trade Summary

Net Seller: 1,688 shares

Net Sell 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Sold 1,688 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,688	$17.8855	$30K

Holdings After Transaction: Common Stock — 990,374 shares (Direct)

Footnotes (2)

1. F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
2. F2. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Key Figures

Shares sold: 1,688 shares Weighted-average sale price: $17.8855 per share Shares held after transaction: 990,374 shares +2 more

5 metrics

Shares sold 1,688 shares Open-market sale on 2026-06-02 to satisfy tax withholding

Weighted-average sale price $17.8855 per share Multiple transactions between $17.63 and $18.10

Shares held after transaction 990,374 shares Direct ownership following the 1,688-share sale

Transaction code S (Sale in open market or private transaction) Form 4 classification of the non-derivative transaction

RSU grant date February 25, 2025 Restricted stock units whose vesting triggered tax obligations

Key Terms

restricted stock units, weighted-average sale price, open-market sale, tax withholding obligations

4 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted-average sale price financial

"The reported price reflects the weighted-average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligations financial

"sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fulgent Genetics (FLGT) report for Hanlin Gao?

Fulgent Genetics reported that Chief Scientific Officer Hanlin Gao sold 1,688 shares of common stock. The transaction was an open-market sale at a weighted-average price of $17.8855 per share, tied to tax obligations from vested restricted stock units.

Why did Hanlin Gao sell shares of Fulgent Genetics (FLGT)?

Hanlin Gao sold the shares to cover tax withholding obligations from vesting restricted stock units. These RSUs were granted on February 25, 2025, and the sale was specifically to satisfy the related tax liabilities rather than a discretionary portfolio decision.

At what price did Hanlin Gao’s Fulgent Genetics (FLGT) share sale occur?

The reported weighted-average sale price was $17.8855 per share. The shares were sold in multiple transactions within a price range of $17.63 to $18.10, with the filing disclosing the consolidated weighted-average figure for simplicity.

How many Fulgent Genetics (FLGT) shares does Hanlin Gao hold after the sale?

After the reported sale, Hanlin Gao directly holds 990,374 shares of Fulgent Genetics common stock. This post-transaction holding shows he retains a substantial equity position in the company despite selling shares for tax-related reasons.

Was Hanlin Gao’s Fulgent Genetics (FLGT) sale a routine tax transaction?

Yes. The filing states the 1,688 shares were sold to satisfy tax withholding obligations from vesting restricted stock units. Such tax-driven sales are common for equity compensation and do not necessarily reflect a change in the insider’s outlook.

What price range covered Hanlin Gao’s Fulgent Genetics (FLGT) share sales?

The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10 per share. The Form 4 reports a weighted-average sale price of $17.8855 and notes that detailed trade data is available upon request to relevant parties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S		1,688(1)	D	$17.8855(2)	990,374	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

2. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)